LYRA - Lyra Therapeutics pops 8% on positive LYR-210 results in chronic rhinosinusitis

Lyra Therapeutics (LYRA) perks up 8.3% premarket after announcing positive topline results from the pharmacokinetic ((PK)) study of LYR-210 in adults with chronic rhinosinusitis ((CRS)), an inflammatory disease of the paranasal sinuses.The study enrolled 24 patients, half of whom received LYR-210 2500 µg and the other half received 7500 µg dose. The study indicated that both doses were safe and well tolerated, with the mean maximum plasma concentration (Cmax) observed with the 7500 ug dose well below Cmax established for FDA-approved formulations of mometasone furoate ((MF)).Data obtained from the study are supportive of LYR-210’s safety profile and provide a PK bridge to the established safety of MF for a 505(b)(2) pathway for NDA submission.MF blood plasma levels observed support LYR-210’s ability to deliver consistent and steady dosing over the entire treatment period of 6 months.

For further details see:

Lyra Therapeutics pops 8% on positive LYR-210 results in chronic rhinosinusitis